Email Updates

You are here

Home

7 DECEMBER 2018 VOLUME 19 ISSUE 49

Media Coverage

  • Vietnam rolls out national program on HIV prevention drug

    PrEP services would be provided in 11 provinces by 2020 and aim to get 7,300 registrants.

    December 7, 2018
    PrEP
    VnExpress International

  • UNAIDS report: 9 million are likely HIV positive and don't know it

    About 9.4 million people are likely HIV-positive and don't know it. That's a key finding from a new report from UNAIDS — and it's why the theme of this month's World AIDS Day is "Know your HIV status."

    December 7, 2018
    General
    NPR

  • An AIDS cure

    American immunologist and Director at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health in the U.S., Dr. Anthony Fauci was a young doctor when he saw his first HIV/AIDS case. This was in 1981, and they were treating a strange illness that had no name. The now 78 year old and colleagues moved to treating opportunistic infections until 1987 when he took part in the study that gave the world the first HIV drug.

    December 5, 2018
    Cure
    Independent

  • The impact PEPFAR had on HIV/AIDS in Africa

    US Global Aids Coordinator, Amb. Deborah Birx, discusses the Emergency Plan for AIDS Relief or PEPFAR and its impact on HIV/AIDS in Africa.

    December 5, 2018
    General
    MSNBC

  • AIDS funding from private sources drops $37M in 2017

    Philanthropic funding to fight the global AIDS epidemic dropped 5 percent last year, compared with 2016, for a decrease of about $37 million, according to a new report from Funders Concerned About AIDS (FCAA). This includes private support from groups ranging from The Bill & Melinda Gates Foundation to pharmaceutical giant Gilead Sciences.

    December 5, 2018
    General
    POZ

  • Huge news: Johnson & Johnson is trialling an HIV vaccine

    The HIV vaccine is currently being trialled in a programme called “Imbokodo” (meaning “rock” in Zulu) from the saying “You strike a woman, you strike a rock” and is backed by the Bill and Melinda Gates Foundation. The vaccine is being trialled by women between the ages of 18 and 35 years in South Africa and Zimbabwe.

    December 5, 2018
    HIV Vaccine
    Women's Health

  • Use sport to promote health among Namibians

    Minister of Health and Social Services Bernhard Haufiku says sport and other gatherings can be successfully used to promote health among Namibians. In line with this, he was listing examples, such as HIV testing, voluntary male circumcision and various others. Haufiku made these remarks during the 30th commemoration of World Aids Day, which took place at Okongo in the Ohangwena region over the weekend.

    December 5, 2018
    General
    nbc

  • Trump Administration threatens future of HIV research hub

    The Trump administration has thrown into doubt a multimillion-dollar research contract to test new treatments for HIV that relies on fetal tissue — work targeted by antiabortion lawmakers and social conservatives aligned with the president.

    December 4, 2018
    Cure, General, Treatment
    Washington Post

  • Researchers want to trial HIV testing kits in Brisbane vending machines

    A Queensland research team are set to make HIV testing kits available in two Brisbane vending machines in a pilot program to increase testing rates.

    December 4, 2018
    General
    Q News

  • Drug buyers' clubs aim to tackle HIV prevention 'crisis'

    A new generation of drug buyers’ clubs like those set up at the height of the AIDS epidemic is seeking to combat a “crisis” in preventing new HIV infections by providing access to cheap generics of a breakthrough prophylactic.

    December 3, 2018
    PrEP
    Reuters

  • As Tanzania's LGBT fear for their lives, HIV will thrive

    Those unable to flee are instead pushed underground and into hiding, kept from entering the outside world -- which blocks their access to health services, such as those protecting against HIV/AIDS.

    December 3, 2018
    General
    CNN

  • CD4 count recovery: French study reaffirms why it is important to test and treat HIV early

    Seven-in-ten people with HIV taking combined antiretroviral therapy for the first time recover their CD4 cell count to above 500 cells/mm3, French researchers report in AIDS. Having a higher CD4 cell count and a higher CD4/CD8 ratio at the time of starting treatment predicted CD4 recovery (strongly, for the former; to a certain extent, for the latter).

    December 3, 2018
    Treatment
    aidsmap

  • South Africa sleeping on the most successful HIV weapons

    Oral pre-exposure prophylaxis (PrEP), taken as a once-daily pill, has been hailed the world over as one of the major HIV prevention interventions in the fight against AIDS. Yet, apart form sex workers, very few South Africans are using PrEP or even know it exists.

    December 3, 2018
    PrEP
    Health-E

  • HIV mother to child transmission drops to 1 percent in a decade

    Although the rate of mother-to-child transmission of HIV has dropped from 20 percent to 1 percent over the past 10 years, the KZN MEC for Health vows to completely eradicate it. Speaking in light of World AIDS Day, MEC Dhlomo said the focus should now be on ensuring that not a single baby acquires HIV from their mother.

    December 3, 2018
    General
    IOL

  • WHO: HIV epidemic spreads at alarming rate in Pakistan

    Pakistan is registering approximately 20,000 new HIV infections annually, the highest rate of increase among all countries in the region, warns the World Health Organization (WHO).

    December 2, 2018
    VOA News

  • Is the US an appropriate place to hold an international AIDS conference?

    This World AIDS Day again finds the United States as a recognized leader of the global AIDS response, but at the same time a controversial choice as host of the next International AIDS Conference, which is scheduled for July 2020 in Oakland and San Francisco.

    December 1, 2018
    General
    The Hill

  • The future of HIV treatment might not involve pills

    One path researchers are exploring is a long-acting, injectable version of anti-HIV drugs, which people would receive about every eight weeks. Like the daily pills, these drugs prevent HIV from making more copies of itself–but they are delivered in different formulations, including nanoparticles that allow small amounts to be released slowly over longer periods of time.

    December 1, 2018
    Treatment
    TIME

  • Namibia's success in the fight against HIV

    Namibia used to have one of the highest HIV-prevalence rates in the world, but in the past 15 years, the number of new HIV infections has halved.

    December 1, 2018
    General
    BBC

  • Montreal doctor develops app for at-home HIV testing

    A Montreal doctor has created an app allowing people to have access to HIV testing from home.

    December 1, 2018
    General
    CBC

  • The long journey researchers face in finding a cure for HIV/Aids

    When it comes to HIV, it took scientists 22 years to realise the modest results from the Thailand trial (RV144) in 2009.

    December 1, 2018
    HIV Vaccine, Cure
    The East African

  • With Black women at high risk for HIV, why are so few taking the prevention pill?

    One in 48 Black women in the United States will contract HIV in her lifetime. But knowledge of—and access to—the pill that can prevent infection remains a problem.

    November 30, 2018
    PrEP
    Rewire.News

  • The HIV epidemic won’t end until we address health disparities in communities of color

    Nearly five decades after the first HIV cases were reported in the United States, an epidemic persists. Despite effective antiretroviral medications for both treatment and prevention, new cases continue to mount, with nearly 39,000 new HIV diagnoses in 2017 alone. But experts agree the country has the tools to finally end the epidemic at home by 2025.

    November 30, 2018
    General
    Huffington Post

  • ‘One size is not going to fit all’: The need for more HIV prevention methods

    NIAID recently announced plans to discontinue funding research into topical drugs known as microbicides if they only work locally. Instead, they are doubling down on solutions that can protect a person no matter where in the body they are exposed to the virus. This means pills and injections of long-acting HIV prevention drugs now in development. If topical drugs can be re-engineered to protect the whole body, they could also be funded, said Carl Dieffenbach, director of NIAID’s Division of AIDS.

    November 29, 2018
    General, Microbicides, PrEP
    Rewire.News

  • The unexpected effects of the HIV prevention pill

    PrEP is great at blocking HIV, but as its use grows, so do fears that people will be more sexually reckless and spread other STIs. But researchers are coming to think that the opposite could be true.

    November 27, 2018
    PrEP
    Mosaic

Published Research

Announcements